Prostanoids for critical limb ischemia

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2007, Pages

  Ruffolo, Antonio J ^a   Romano, M ^b   Ciapponi, A ^b  

^a Boehringer Ingelheim   (Argentina)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; CILOSTAZOL; CISAPROST; ILOPROST; NAFTIDROFURYL; PENTOXIFYLLINE; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN E1; PROSTANOID;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA EXTRACTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFORMATION PROCESSING; LIMB ISCHEMIA; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL ANALYSIS;

EID: 44949112289     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006544     Document Type: Review

References (42)

1. Albers 1992 Albers M, Fratezi AC, De Luccia N. Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease. Journal of Vascular Surgery 1992;16(1):54-9.
2. Anonymous 1991 Anonymous. Second European Consensus Document on chronic critical leg ischemia. Circulation 1991;84(4 Suppl):1-26.
3. Balzer 1991 Balzer K, Bechara G, Bisler H, Clevert MD, Diehm C, Heisig G, et al.Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease: A double blind placebo controlled trial with iloprost. International Angiology 1991;10(4):229-32.
4. Barani 2006 Barani J, Mattiasson I, Lindblad B, Gottsater A. Cardiac function, inflammatory mediators and mortality in critical limb ishemia. Angiology 2006;57(4):437-44.
5. Baumgartner 1998 Baumgartner I, Pieczec A, Manor O, Blair R, Kearney M, Walsh K, et al.Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97(12):1114-23.
6. Bertelé 1999 Bertelé V, Roncaglioni MC, Pangrazzi J, et al.Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. European Journal of Vascular & Endovascular Surgery 1999;18(5):401-10.
7. Brock 1990 Brock FE, Abri O, Baitsch G, Bechara G, Beck K, Corovic D, et al.Iloprost in the treatment of ischemic tissue lessions in diabetics: Results of a placebo - controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift 1990;120(40):1447-82.
8. Catalano 1993 Catalano M. Epidemiology of critical limb ischemia: north italian data. European Journal of Medicine 1993;2(1):11-4.
9. Creutzig 2004 Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages II and IV. Vasa 2004;33(3):137-44.
10. Criqui 1992 Criqui MH, Langer RD, Fronek A, Fiegelson HS, Klauber MR. Mortality over a period of 10 years in patients with peripheral arterial disease. New England Journal of Medicine 1992;326(6):381-6.
11. Cronenwett 1984 Cronenwett JL, Warner KG, Zeleneck GB, Whitehouse WM Jr, Graham LM, Lindenauer M, et al.Intermittent claudication. Current results of non operative management. Archives of Surgery 1984;119(4):430- 6.
12. Daniel 1989 Daniel MC, Cronenwett JL. Basic data related to the natural history of intermittent claudication. Annals of Vascular Surgery 1986;3(3):273-7.
13. Dormandy 1996 Dormandy JA. Prostanoid drug therapy for peripheral arterial occlusive disease - the European experience. Vascular Medicine 1996;1(2):155-8.
14. Dormandy 1998 Dormandy JA, Thomas PR. What is the natural history of a critically ischemic patient with and without his leg?. In: GreenhalghRM, JamiesonC, NicolaidesAN editor(s). Limb Salvage and Amputation for Vascular Disease. 11th Edition. Philadelphia: WBSaunders, 1988: 11-26.
15. Dormandy 1999 Dormandy J, Heeck L, Vig S. The fate of patients with critical leg ischemia. Seminars in Vascular Surgery 1999;12(2):142-7.
16. Dormandy 2000 Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). Journal of Vascular Surgery 2000;31(1 Pt 2):S1-S296.
17. Ebskow 1994 Ebskov L, Schroeder TV, Holstein PE. Epidemiology of leg amputation: the influence of vascular surgery. British Journal of Surgery 1994;81(11):1600-3.
18. Ebskow 1999 Ebskov B. Relative mortality and long term survival for the non-diabetic lower limb amputee with vascular insufficiency. Prosthetics & Orthotics International 1999;23(3):209-16.
19. Fowkes 1991 Fowkes FG, Housley E, Cawood EH, et al.Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. International Journal of Epidemiology 1991;20(2):384-92.
20. Hankey 2006 Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006;295(5):547-53.
21. Hirsch 2006 Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Perin JL, et al.ACC/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease. Circulation 2006;113(11):463-654.
22. ICAI Group 1999 The ICAI Group. Prostanoids for chronic critical leg ischemia: results of a randomised open-label trial with prostaglandin E1. Annals of Internal Medicine 1999;130(5):412-21.
23. Isner 1995 Isner JM, Walsh K, Symes J, Pieczek A Takeshita S, Lowry J, et al.Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation 1995;91(11):2687-92.
24. Isner 1996 Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, et al.Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996;348(9024) :370-4.
25. Isner 1998 Isner JM. Arterial gene transfer of naked DNA for therapeutic angiogenesis: Early clinical results. Advanced Drug Delivery Reviews 1998;30(1-3):185-97.
26. Jadad 1996 Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
27. Jelnes 1986 Jelnes R, Gaardsting O, Hougaard Jensen K, Backgaard N, Tonnesen KH, Schroeder T, et al.Fate in intermittent claudication: outcome and risk factors. British Medical Journal Clinical Research Ed 1986; 293(6555):1137-40.
28. Jonanson 1986 Jonason T, Ringqvist J. Changes in peripheral blood pressures after 5 years of follow - up in non operated patients with intermittent claudication. Acta Medica Scandinavica 1986;220(2): 127-32.
29. Juerguens 1960 Juerguens JL, Barker NW, Hines EA Jr. Atherosclerosis obliterans. Review of 520 cases with special reference to pathogenic and prognostic factors. Circulation 1960;21:188-95.
30. Kannel 1994 Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. Journal of Cardiovascular Risk 1994;1(4):333-9.
31. Kazmers 2000 Kazmers A, Perkins AJ, Jacobs LA.Major lower extremity amputation in Veterans Affairs medical centers. Annals of Vascular Surgery 2000;14(3):216-22.
32. Loosemore 1994 Loosemore TM, Chalmers TC, Dormandy JA. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. International Angiology 1994;13(2):133-42.
33. Luther 1994 Luther M. The influence of arterial reconstructive surgery on the outcome of criticial leg ischaemia. European Journal of Vascular Surgery 1994;8(6):682-9.
34. Mackiewicz 2003 Mackiewicz Z, Rimkevicius A, Dudek E, et al.Skeletal muscle regeneration in chronic critical limb ischemia. Acta Medica Lituanica 2003;10(3):147-51.
35. Norgren 1990 Norgren L, Alwmark A, Angqvist KA, Hedberg B, Bergqvist D, Takolander R, et al.A stable prostacyclin analogue (iloprost) in the treatment of ischaemic ulcers of the lower limb: A Scandinavian - Polish placebo controlled, randomised multicenter study. European Journal of Vascular Surgery 1990;4(5):463-7.
36. Novo 2004 Novo S, Coppola G, Milio G. Critical limb ischemia: definition and natural history. Current Drug Targets Cardiovascular & Haematological Disorders 2004;4(3):219-25.
37. Reiter 2003 Reiter M, Bucek RA, Stümpflen A, Minar E, et al.Prostanoids for intermittent claudication (Cochrane review). Cochrane Database of Systematic Reviews 2003, Issue 4.Art. No.: CD000986. DOI: 10.1002/14651858.CD000986.pub2.
38. Rothwell 2005 Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, et al.Population - based study of event - rate, incidence, case fatality, and mortality for all acute events in all arterial territories (Oxford Vascular Study). Lancet 2005;366(9499):1773-83.
39. Tact-Nagoya Tact-Nagoya. Therapeutic Angiogenesis Using Cell Transplantation (TACT( Study. http://clinicaltrials.gov/ct/gui/show/NCT00145262 (accessed 14 February 2007).
40. Talisman Nikol S. The Talisman 2001 Clinical Trial Investigators. Therapeutic angiogenesis with intramuscular NV1FGF improves amputatiuon-free survival in patients with critical limb ischaemia. http://acc06online.acc.org/ Lectures.aspx?sessionId=1&date=12 (accessed 14 February 2007).
41. Trubestein 1989 Trubestein G, von Bary S, Breddin K, Diehm C, Gruss JD, Heinrich H, et al.Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease - a controlled randomised multicenter study. Vasa - Supplementum 1989;28:44-9.
42. Vaestrete 1994 Vaestrete M. prostaglandins in critical limb ischemia. Vascular Medicine Review 1994;5(2):93-5.